Core Viewpoint - Mitsubishi Chemical announced its exit from the coking and carbon materials business operated by its subsidiary, which includes needle coke and pitch coke products, due to a prolonged downturn in the overseas coking market [1] Group 1: Business Exit Details - The company expects a non-recurring loss of approximately 85 billion yen from this business exit [1] - Production of related products is scheduled to cease in the second half of 2027, with sales gradually reducing and equipment to be dismantled promptly after production halts [1] - The exited business generated revenue of 115.7 billion yen for the fiscal year ending March 2025 and employed around 600 staff as of February 2, 2026 [1] Group 2: Market Conditions - The decision to exit is attributed to a persistent slump in steel demand and oversupply in the global coking market, leading to a supply-demand imbalance [1] - The carbon materials production system is closely tied to coke oven operations, meaning that the cessation of coke production will directly impact the cost structure of the carbon materials business [1] - Given the ongoing oversupply and weak demand in the industry, Mitsubishi Chemical believes that stopping coke production is the most viable development option [1] Group 3: Strategic Shift - In recent years, Mitsubishi Chemical has accelerated its exit from traditional petrochemical businesses, having decided at the end of 2021 to phase out oil and coal chemical operations over several years [1] - The company has also announced exits from the PET bottle business and has undertaken a series of restructuring actions, including the closure of the Mitsubishi Chemical Shimonoseki and Shinryo Hama factories [1]

Group 1 - Mitsubishi Chemical announced the exit from its coal division's operations in the coking and carbon materials business, including needle coke and pitch coke products [1] - The company expects a non-recurring loss of approximately 85 billion yen from this business exit [1] - The production plan for related products is set to cease in the second half of 2027, with sales gradually reducing and equipment to be dismantled post-production [1] Group 2 - The exited business generated revenue of 115.7 billion yen for the fiscal year ending March 2025 and employed around 600 staff as of February 2, 2026 [1] - The decision to exit was influenced by a prolonged downturn in the overseas coking coal market, characterized by weak steel demand and oversupply of competing products [1] - The carbon materials production system is closely tied to coke oven operations, and the cessation of coke production will directly impact the cost structure of the carbon materials business [1]

Core Insights - UnitedHealth Group has agreed to sell its remaining South American business, Banmedica, to Brazilian private equity firm Patria Investments for approximately $1 billion [1] - The deal was signed last Saturday and is expected to be officially announced this week [1] - UnitedHealth has been exiting the Latin American market since 2022, having previously sold its operations in Brazil and Peru [1] Company Strategy - The sale of Banmedica, which operates in Colombia and Chile, has been under negotiation for nearly a year [1] - As of June this year, Banmedica had 1.7 million health insurance members, 7 hospitals, and 47 medical centers [1] - The exit from the region aligns with UnitedHealth's efforts under CEO Stephen Hemsley to reduce distractions and refocus on core operations [1] Financial Impact - UnitedHealth reported a loss of $8.3 billion last year due to the sale of its South American operations, with $7.1 billion attributed to exiting the Brazilian market and $1.2 billion from the Banmedica business [1] - The company raised its annual profit forecast in October and expects to return to growth by 2026 [1]